期刊
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
卷 8, 期 5, 页码 526-532出版社
WILEY-BLACKWELL
DOI: 10.1111/cts.12255
关键词
Phase I; new agents; FDA; trials
资金
- National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR001105, UL1TR001117, 2UL1TR000433, UL1 TR000042]
PurposeThe Food and Drug Administration Expanded Access (EA) program and Right-to-Try legislation aim to provide seriously ill patients who have no other comparable treatment options to gain access to investigational drugs and biological agents. Physicians and institutions need to understand these programs to respond to questions and requests for access. MethodsFDA EA programs and state and federal legislative efforts to provide investigational products to patients by circumventing FDA regulations were summarized and compared. ResultsThe FDA EA program includes Single Patient-Investigational New Drug (SP-IND), Emergency SP-IND, Intermediate Sized Population IND, and Treatment IND. Approval rates for all categories exceed 99%. Approval requires FDA and Institutional Review Board (IRB) approval, and cooperation of the pharmaceutical partner is essential. Right-to-Try legislation bypasses some of these steps, but provides no regulatory or safety oversight. ConclusionThe FDA EA program is a reasonable option for patients for whom all other therapeutic interventions have failed. The SP-IND not only provides patient access to new drugs, but also maintains a balance between immediacy and necessary patient protection. Rather than circumventing existing FDA regulations through proposed legislation, it seems more judicious to provide the knowledge and means to meet the EA requirements.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据